Salix Pharmaceuticals, Ltd.
1700 Perimeter Park Drive
Morrisville
North Carolina
27560
United States
Tel: 919-862-1000
Fax: 919-862-1095
Website: http://www.salix.com/
399 articles about Salix Pharmaceuticals, Ltd.
-
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
3/6/2024
Bausch Health Companies Inc. today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma.
-
Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute
1/8/2024
Bausch Health Companies Inc. today announced that, as scheduled, oral arguments were heard today at the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD et al v. Norwich Pharmaceuticals, Inc.
-
Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day
12/5/2023
Salix Pharmaceuticals, the gastroenterology division of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), The U.S. Pain Foundation (USPF), and The International Foundation for Gastrointestinal Disorders (IFFGD) today announced they are joining forces to declare Tuesday, Dec. 5, Opioid-Induced Constipation (OIC) Awareness Day.
-
New Analysis Indicates That a Majority of Overt Hepatic Encephalopathy (OHE) Patients May Face Delays in Treatment Initiation and Gaps During Treatment for Access to Treatment Indicated to Reduce Risk for OHE Recurrence
10/17/2023
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced findings from a retrospective database analysis of adjudicated claims data that examined the impact of access barriers for commercially-insured adults prescribed Xifaxan® for reduction in risk of overt hepatic encephalopathy recurrence in adults.
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase in Chronic Liver Disease and Cirrhosis-Related Deaths Marking These as Ninth Leading Cause of Death in U.S.
10/10/2023
Salix Pharmaceuticals today released the Salix Liver Health Trends Report, Third Edition, which documents the evolving crisis of chronic liver disease (CLD), showing a 9% increase in CLD and cirrhosis mortality marking these as the ninth leading cause of death in the United States in 2021.
-
Salix Pharmaceuticals Partners with Bellamy Young
10/4/2023
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its partnership with award-winning actor Bellamy Young, who is speaking out to help educate people who are impacted by hepatic encephalopathy (HE), caused by cirrhosis.
-
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
7/11/2023
Bausch Health Companies Inc. (NYSE/TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced the winners of its 2023 Salix Gastrointestinal Health Scholars Program.
-
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
5/8/2023
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.
-
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
4/24/2023
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced a partnership with the Colorectal Cancer Alliance, the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase awareness and access to preventative colorectal screenings in medically underserved communities.
-
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
4/4/2023
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome or chronic idiopathic constipation.
-
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
12/1/2022
Salix Pharmaceuticals today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December.
-
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
10/24/2022
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.
-
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population
10/12/2022
Salix Pharmaceuticals, the gastroenterology business of Bausch Health Companies Inc., released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complications.
-
SALIX PHARMACEUTICALS APPLAUDS IMPLEMENTATION OF K76.82 - A NEW ICD-10 CODE FOR HEPATIC ENCEPHALOPATHY
10/3/2022
Bausch Health Companies Inc. announced today, their endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain.
-
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
8/10/2022
Bausch Health Companies Inc. today announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.
-
Axcella is prioritizing its clinical development portfolio to focus on its investigative assets for COVID-19 and non-alcoholic steatohepatitis (NASH) after abrupt leadership resignations.
-
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
5/18/2022
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022.
-
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
12/3/2021
Bausch Health Companies Inc. today introduced a collection of digital and social activations aimed at helping adult patients with opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
-
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
11/11/2021
Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals announced two abstracts featuring new data for rifaximin are being presented at The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases, which is taking place virtually Nov. 12-15, 2021.
-
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
10/25/2021
Research Findings for XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and RELISTOR® (methylnaltrexone bromide) Will be Presented